Below is the complete patent application following the provided outline and based on the research paper.  

---

# DESCRIPTION  

## INTRODUCTION  

The present invention relates to a novel method for detecting genetic alterations in multiple myeloma (MM) using a targeted sequencing platform. Specifically, the invention provides a comprehensive approach to simultaneously identify copy number variants (CNVs), single-nucleotide variants (SNVs), and translocations associated with MM pathogenesis and progression. The disclosed method enables precise detection of clinically relevant mutations, including novel translocations involving the IGLL5 gene, which may serve as biomarkers for disease prognosis and therapeutic targeting.  

Multiple myeloma is a malignancy of plasma B cells characterized by a diverse spectrum of genetic abnormalities, including hyperdiploidy, IGH translocations, and secondary mutations in genes such as KRAS, NRAS, and MYC. Current diagnostic methods, including fluorescence in situ hybridization (FISH) and exome sequencing, are limited in their ability to simultaneously detect multiple mutation types with high sensitivity and specificity. The present invention addresses these limitations by providing a unified sequencing platform that integrates targeted capture of genomic regions with optimized bioinformatics analysis for accurate mutation calling.  

## SUMMARY  

The invention provides a targeted sequencing platform designed to detect CNVs, SNVs, and translocations in multiple myeloma. The platform utilizes a custom-designed probe set covering 3.3 Mb of genomic space, including exonic, untranslated, and splice site regions of 465 genes implicated in MM and/or other cancers. Additionally, the platform includes probes tiled across the IGH locus and known translocation partners (e.g., CCND1, CCND3, FGFR3, MAF, MAFB, WHSC1, WWOX) to enhance detection of structural rearrangements.  

Key advantages of the invention include:  
1. **Comprehensive mutation detection**: The platform simultaneously identifies CNVs, SNVs, and translocations, enabling integrative analysis of mutation co-occurrence and mutual exclusivity.  
2. **High sensitivity and specificity**: Optimized computational methods reduce false positives in CNV and translocation calling, improving diagnostic accuracy.  
3. **Novel biomarker discovery**: The platform detects rare translocations involving IGLL5, which are associated with disease progression and may serve as prognostic indicators.  
4. **Clinical utility**: The method facilitates personalized treatment strategies by identifying high-risk mutations and potential therapeutic targets.  

## DETAILED DESCRIPTION  

### DETAILED DESCRIPTION  

The invention encompasses a targeted sequencing method comprising the following steps:  

1. **Probe Design**: A custom probe set is designed to hybridize with 3.3 Mb of genomic DNA, including:  
   - Exonic, untranslated, and splice site regions of 465 genes implicated in MM or other cancers.  
   - The entire IGH locus, including variable (IGHV), diversity (IGHD), joining (IGHJ), and constant/switch regions.  
   - Canonical IGH translocation partners (CCND1, CCND3, FGFR3, MAF, MAFB, WHSC1, WWOX) and MYC.  

2. **Library Preparation and Sequencing**:  
   - DNA is extracted from tumor (CD138+ bone marrow cells) and paired normal (blood) samples.  
   - Sequencing libraries are prepared, hybridized to the probes, and sequenced using high-throughput platforms (e.g., Illumina HiSeq).  

3. **Bioinformatic Analysis**:  
   - **SNV Calling**: Acquired SNVs are identified using multiple variant callers (e.g., MuTect, VarScan2) and filtered for somatic mutations.  
   - **CNV Calling**: Copy number alterations are detected using depth-of-coverage ratios (e.g., CopyCAT2) with noise reduction algorithms.  
   - **Translocation Calling**: Structural rearrangements are identified using split-read and discordant-pair analysis (e.g., LUMPY), followed by machine learning-based filtering to minimize false positives.  

4. **Integrative Mutation Analysis**:  
   - Co-occurrence and mutual exclusivity patterns among CNVs, SNVs, and translocations are analyzed to identify pathogenic interactions (e.g., IGLL5 mutations being mutually exclusive with RAS mutations).  
   - Novel translocations (e.g., t(14;22) involving IGLL5) are validated using PCR and sequencing.  

5. **Prognostic and Therapeutic Applications**:  
   - Detected mutations are correlated with clinical outcomes to stratify patients into risk groups.  
   - Overexpressed genes (e.g., DERL3) are evaluated as potential therapeutic targets.  

## EXAMPLES  

### Example 1  

**Detection of Hyperdiploidy and Focal CNVs**  
In a cohort of 95 MM patients, the platform identified hyperdiploidy (trisomies of odd-numbered chromosomes) in 50% of samples. Additionally, focal CNVs, including a homozygous deletion spanning BRCA2, were detected with high confidence using depth ratio analysis.  

### Example 2  

**Identification of Canonical IGH Translocations**  
The platform detected known IGH translocations (e.g., t(4;14), t(11;14)) at expected frequencies (Table 1). Breakpoints were predominantly located within the IGH constant region, consistent with prior studies.  

### Example 3  

**Discovery of Novel IGLL5 Translocations**  
A novel t(14;22) translocation involving IGLL5 was validated in one patient sample. PCR amplification confirmed the breakpoint, and RNA-seq analysis revealed overexpression of DERL3, a nearby gene, suggesting enhancer-mediated dysregulation.  

### Example 4  

**Detection of MYC Translocations**  
Intra- and inter-chromosomal MYC translocations were identified in 6% of samples. A machine learning filter reduced false positives, improving specificity compared to unfiltered calls.  

### Example 5  

**High-Frequency SNVs in IGLL5**  
Non-synonymous IGLL5 mutations were detected in 18% of samples, with enrichment for AID-induced mutations. These mutations were mutually exclusive with RAS mutations and associated with poor prognosis.  

### Example 6  

**Sequencing Depth Optimization**  
Deep sequencing (1,259×) of 15 samples yielded few additional variants compared to standard depth (100×), demonstrating that moderate coverage suffices for clinical applications.  

### Example 7  

**Mutual Exclusivity of del(6q) and RAS Mutations**  
Integrative analysis revealed that deletions of chromosome 6q were mutually exclusive with RAS mutations, suggesting alternative pathways in MM progression.  

### Example 8  

**Validation Against Exome and FISH Data**  
The platform showed high concordance with exome sequencing (R² = 0.85 for SNVs) and FISH (100% precision for IGH translocations), confirming its reliability.  

### Example 9  

**Prognostic Utility of IGLL5 Mutations**  
Kaplan-Meier analysis demonstrated that patients with IGLL5 mutations had significantly shorter progression-free survival (p = 0.03), supporting its role as a biomarker.  

---  

This patent application provides a comprehensive and clinically actionable method for detecting multiple myeloma-associated mutations, enabling improved diagnosis, prognosis, and therapeutic decision-making.